XML 20 R7.htm IDEA: XBRL DOCUMENT v3.20.2
Consolidated Statements of Cash Flows - USD ($)
$ in Millions
 12 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2018
CASH FLOWS FROM OPERATING ACTIVITIES:      
Net income (loss) attributable to Myriad Genetics, Inc. stockholders $ (199.5) $ 4.6 $ 133.3
Adjustments to reconcile net income (loss) to net cash provided by operating activities:      
Depreciation and amortization 72.0 73.0 54.4
Non-cash interest expense 0.5 0.4 0.2
Gain on deconsolidation of subsidiary (1.0)    
Gain on disposition of assets   (0.9) (0.2)
Share-based compensation expense 25.2 33.5 27.1
Deferred income taxes (55.8) 18.6 (23.5)
Unrecognized tax benefits 1.7 (5.5) (0.3)
Impairment of goodwill and intangible assets 99.7    
Change in fair value of contingent consideration 2.8 (1.4) (60.9)
Payment of contingent consideration   (1.5) (22.7)
Changes in assets and liabilities:      
Prepaid expenses 2.2 (3.2) 3.3
Trade accounts receivable 64.0 (18.2) (9.1)
Other receivables 0.6 (0.7) 1.1
Inventory 1.6 8.0 7.9
Prepaid taxes 25.1 (25.1)  
Accounts payable (10.7) 1.1 4.0
Accrued liabilities 1.6 1.5 1.4
Deferred revenue 30.7 (0.5) (0.1)
Net cash provided by operating activities 60.7 83.7 115.9
CASH FLOWS FROM INVESTING ACTIVITIES      
Capital expenditures (10.2) (8.6) (8.4)
Acquisitions, net of cash acquired   (278.5)  
Proceeds from sale of subsidiary 21.3    
Purchases of marketable investment securities (60.8) (78.5) (80.9)
Proceeds from maturities and sales of marketable investment securities 69.0 79.2 77.7
Net cash provided by (used in) investing activities 19.3 (286.4) (11.6)
CASH FLOWS FROM FINANCING ACTIVITIES:      
Net proceeds from common stock issued under share-based compensation plans 3.5 8.7 36.9
Proceeds from revolving credit facility   340.0 53.0
Repayment of revolving credit facility (8.6) (115.0) (143.0)
Payment of contingent consideration recognized at acquisition (3.9)   (42.4)
Fees associated with refinancing of revolving credit facility (1.0) (1.4)  
Repurchase and retirement of common stock   (50.0)  
Proceeds from non-controlling interest     0.5
Net cash provided by (used in) financing activities (10.0) 182.3 (95.0)
Effect of foreign exchange rates on cash and cash equivalents 0.5 2.7 (0.8)
Net increase (decrease) in cash and cash equivalents 70.5 (17.7) 8.5
Cash and cash equivalents at beginning of year 93.2 110.9 102.4
Cash and cash equivalents at end of year $ 163.7 $ 93.2 $ 110.9